Press Releases

12/15/2022

Oncology

Fight Colorectal Cancer Funds Tempus Research Fellow to Identify Gaps in Colorectal Cancer Research

Fight Colorectal Cancer (Fight CRC) announced today that they have committed $150,000 per year for a three-year research fellowship to study clinical data at Tempus, a leader in artificial intelligence and precision medicine. The awarded researcher will receive access to Tempus de-identified datasets and analytical platform to ide...

12/06/2022

Oncology

Tempus Announces Six Abstracts Accepted for Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the 2022 San Antonio Breast Cancer Symposium, which convenes from December 6-10, in San Antonio, Texas. Tempus continues to be a leader in advancing breast cancer research, demonstrated in the six abstract...

11/09/2022

Oncology

Tempus Announces Six Abstracts Accepted for Presentation at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, which convenes in Boston, Massachusetts, from November 8-12, 2022. Tempus continues to be a leader in advancing immunotherapy research...

11/04/2022

Cardiology

Tempus Announces Six Abstracts Accepted for Presentation at the American Heart Association Scientific Sessions 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced that six abstracts, resulting from its strategic partnership with Geisinger, were accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2022, which convenes in Chicago, Illinois from November 5-7, 2022. This is the fourth year that Tempus has presented w...

11/03/2022

Tempus Launches First Cardiology Prospective Study for its AI-Enabled Predictive Tests

In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of a multi-center study titled, ...

10/27/2022

Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research

Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegheny Health Network...

10/25/2022

Tempus Announces Dr. Kate Sasser as Chief Scientific Officer

Tempus, a leader in artificial intelligence and precision medicine, today announced that Kate Sasser, PhD, is joining the company as its Chief Scientific Officer. Dr. Sasser brings over twenty year’s experience in translational research, precision medicine, data science, and drug discovery and development across the biotech and pharmaceutical i...

10/20/2022

Tempus Announces $275 Million in Funding

Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same price per share as its previous fundraising round, and debt financing from funds managed by Ares Management. In total, Tempu...

10/18/2022

GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D

Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology Access will enable GSK to improve clinical trial design, speed up enrollment and identify drug targets GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision me...

10/06/2022

Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232). Tempus’ CDx test, which will be developed on Tempus’ xT platform,...

NEWS

Media Coverage

Additional Partnerships